ZymoGenetics Names Gilead Executive to Board
SEATTLE (AP) — Biotechnology company ZymoGenetics Inc. on Thursday named Gilead Sciences executive A. Bruce Montgomery to its board of directors, replacing Lars Sorensen.
Montgomery is in charge of Gilead's respiratory therapeutics division and the founder and former CEO of Corus Pharmaceuticals. ZymoGenetics said he has also worked with Genentech, which is now a division of Swiss drugmaker Roche.
ZymoGenetics said Sorensen resigned from its board, giving up a seat he has held since January 1996. Sorensen is the president and CEO of Novo Nordisk AS, a Danish drugmaker.
The company gets most of its revenue from sales of Recothrom, a drug that is used to reduce bleeding during surgery. Recothrom is marketed by German drugmaker Bayer.